Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.

Nat Commun · 2025 · PMC11698957 · PMID 39753553

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

near-significantno p-value reported

Although the numbers were small, we were able to see near-significant differences between the PFS of MRD-negative cases and those who did not achieve or sustain MRD-negativity.

also in 2,306 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.